Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

Eli Lilly and Profluent will harness AI to discover and develop recombinases for precise, large-scale gene editing.

A weak Q1 for Novartis that was heavily impacted by generics erosion showcases that the billions of dollars being spent by the pharma industry to shore up revenue streams amid a looming patent cliff ...

Rocket Pharmaceuticals has signed an agreement to sell its rare paediatric disease PRV for $180m to advance its gene therapy pipeline.

Seaport will use the funds for its neuropsychiatric drug pipeline, while Hemab will focus on bleeding disorder medicines.

BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, buying the company for $14.50 per share in an all-cash deal.

AstraZeneca has received approval from the FDA for the subcutaneous self-administration of Saphnelo using the Saphnelo pen for SLE.

Pharmaceutical trade associations across the Nordic region have reacted with vigilance to a recent GlobalData report that highlighted the potential effect on product launch and withdrawal trends in ...

Merck KGaA and Remepy will work in tandem to develop drug-digital therapy combinations for a rare cancer indication.

With an uptick and increasingly even spread of capital across the space, the BIA’s Martin Turner is optimistic for British biotech’s future.

AI capabilities within pharma are evolving from add-on to an arm of core business demanding overhauled AI governance.

Ajax’s lead asset is AJ1-11095, a once-daily Type II JAK2 inhibitor taken orally, which is currently in a Phase I trial.